Clinical Trials in Phoenix

Showing 3141-3160 of 14,291 trials

Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

NCT06401642

Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related peptide (CGRP) migraine preventive treatments.

Migraine

Mayo Clinic200 participantsStarted Mar 2024

Phoenix, Arizona, United States

Active Not RecruitingPhase 3< 1 mile

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

NCT00978458

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with or without temozolomide in treating patients with low-grade glioma. PURPOSE: This randomized phase III trial is studying radiation therapy so see how well it works when given together with or without temozolomide in treating patients with low-grade glioma.

Brain and Central Nervous System TumorsNeurotoxicity

Eastern Cooperative Oncology Group540 participantsStarted Nov 2009

Birmingham, Alabama, United States • Phoenix, Arizona, United States • La Jolla, California, United States +165 more locations

Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Find Trials by Condition in Phoenix

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Cervical Traction to Reduce Gabaergic Medication Use for Neuropathic Itch

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Phase 2b Study of ALTO-100 in MDD

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

OCS DCD Heart + CAP Continued Follow-Up

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

FebriDx® Method Comparison Study Protocol

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

International Rare Brain Tumor Registry

Skin Reactions Related to Thoracic Implantable Chamber Dressings